Castle Biosciences, Inc. (CSTL) Guidance & Earnings Results
On 2026-07-30 Castle Biosciences, Inc. raised guidance: "FY2026 revenue guidance raised from $345-355M to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CSTLCastle Biosciences, Inc.Follow CSTL — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Raised | FY2026 revenue guidance raised from $345-355M to $365-375M · full year |
| 6 May 26 | Raised | FY2026 revenue guidance raised to $345-355M from $340-350M · full year |
| 26 Feb 26 | Raised | Exceeded 2025 guidance; no explicit 2026 guidance provided but management expresses confidence |
| 13 Jan 26 | Raised | 2025 total revenue >$340M vs guided $327-335M · full year |
| 3 Nov 25 | Raised | Full-year 2025 revenue guidance raised to $327-335 million from $310-320 million · full year |
| 4 Aug 25 | Raised | FY2025 revenue raised to $310-320M from $287-297M · full year |
Castle Biosciences, Inc. — questions
- What guidance did Castle Biosciences, Inc. give?
- On 2026-07-30: "FY2026 revenue guidance raised from $345-355M to $365-375M"
- When does Castle Biosciences, Inc. report earnings?
- Castle Biosciences, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Castle Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.